SCHEMBL29659799

SCHEMBL29659799

COC(=O)c1ccc2oc(Cc3ccccc3OC)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.50
TP53 P04637 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
STAT3 P40763 1/20 0.47
KMT2A Q03164 1/20 0.47
PLA2G2A P14555 1/20 0.46
RAB9A P51151 5/20 0.45
NPC1 O15118 3/20 0.45
PDE10A Q9Y233 1/20 0.45
POLB P06746 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 3/20 0.43
P2RY14 Q15391 1/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22775472 1.00 MAPT (0.50) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL22775709 0.90 MAPT (0.51) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL29659773 0.90 MAPT (0.51) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL3118574 0.83 MAPT (0.61) MAPTTP53RAB9ANPC1POLB
SCHEMBL22775854 0.81 MAPT (0.51) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL29431313 0.81 MAPT (0.51) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL22787701 0.79 MAPT (0.42) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL29431214 0.79 MAPT (0.42) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL29613712 0.79 MAPT (0.42) MAPTTP53SMN1; SMN2MEN1STAT3
SCHEMBL17221764 0.79 GAA (0.57) MAPTTP53SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552770-B2 Compounds for treating respiratory disease TMEM16A LIMITED (GB) 2026-02-17 US disclosed
CN-114269721-B Compounds for the treatment of respiratory diseases TMEM16A有限公司 2024-12-20 CN disclosed
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM16A LTD (GB) 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552770-B2 Compounds for treating respiratory disease TMEM109, SCN1A, SLC16A1 MAPT 1158/4885TP53 4588/4885SMN1; SMN2 454/4885
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM109, SLC16A1, CFTR MAPT 1182/4885TP53 4466/4885SMN1; SMN2 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.